REPORTABLE CANCERS
Virginia Cancer Registry
Certain cancers are reportable to the Virginia Cancer Registry. The Commonwealth of Virginia State Board of Health defines what cancers are reportable in Regulations for Disease Reporting and Control. To access the document at: Click Here
PART I. DEFINITIONS 12 VAC 5-90-10. Definitions. “Cancer” means all carcinomas, sarcomas, melanomas, leukemias, and lymphomas excluding localized basal and squamous cell carcinomas of the skin, except for lesions of the mucous membranes.
PART VIII. CANCER REPORTING
12 VAC 5-90-160. Reportable Cancers and Tumors.
Clinically or pathologically diagnosed cancers, as defined in 12 VAC 5-9010, and benign brain and central nervous system tumors shall be reported to
the Virginia Cancer Registry in the department. Carcinoma in situ of the
cervix is not reportable.
Source:
Commonwealth of Virginia State Board of Health. 2004. Regulations for
Disease Reporting and Control. November 2004, pp. 1, 29.
Reportable:
- All primary malignant neoplasms. Include both in situ and invasive tumors.
- Benign tumors of the brain and central nervous system in the following ICD-O sites: C70.0-C70.9, C71.0-C71.9, C72.0-C72.9, C75.1-C75.3. This includes pituitary tumors.
- Vulvar intraepithelial neoplasia, grade III (VIN III)
- Vaginal intraepithelial neoplasia, grade III (VAIN III)
- Anal intraepithelial neoplasia, grade III (AIN III)
Not Reportable:
- Basal cell and squamous cell carcinomas of the skin
- Exceptions
- Basal and squamous cell carcinomas of the following mucoepidermoid sites
- Lip (C00.0-C00.9)
- Anus and Anal Canal
- Vulva
- Vagina
- Penis and Scrotum
- Other skin malignancies
- Melanomas
- Mycosis fungoides
- Kaposi’s Sarcoma
- Merkel cell tumors
ICD-9-CM Codes for reportable conditions
Use the following ICD-9-CM codes to identify reportable conditions.
- Conditions in bold type are reportable only when diagnosed on or after January 1, 2001.
- Conditions in brackets [ ] and italics are reportable only when the diagnosis date is prior to January 1, 2001.
140 – 199 Malignant neoplasms
AIDS (review cases for AIDS-related malignancies)
200 – 208 Lymphoma/leukemia/multiple myeloma
210-229.9 Benign Neoplasms
230 – 234 Carcinoma in situ (exclude 233.1*)
235.0-238.9 Neoplasms of uncertain behavior
[235.4] Peritoneum/cystadenoma, borderline malignancy
236.0 Endolymphatic stromal myosis/endometrial stromatosis/stromal endometriosis/ stromal myosis, NOS
[236.2] Tumor of ovary/cystadenoma, borderline malignancy of low malignant potential
237.5 Papillary ependymoma
- Papillary meningioma
- Phyllodes tumor, malignant (cystosarcoma phyllodes)
238.4 |
Polycythemia vera |
238.6 |
Plasmacytoma/solitary myeloma |
238.7 |
Acute panmyelosis/chronic myeloproliferative |
|
disease/myelosclerosis with myeloid metaplasia/essential |
|
thrombocythemia/refractory cytopenia with multilineage |
|
dysplasia/myelodysplastic syndrome with 5q |
|
syndrome/therapy related myelodysplastic syndrome |
273.2 |
Alpha heavy chain disease/Franklin disease/gamma heavy |
|
chain disease |
273.3 |
Waldenstrom macroglobulinemia |
273.9 |
Unspecified disorder of immune mechanism (screen for |
|
potential 273.3 miscodes) |
284.9 |
Refractory anemia |
285.0 |
|
288.3 |
Hypereosinophilic syndrome |
289.8 |
Acute myelofibrosis |
V07.3 |
Other prophylactic chemotherapy (screen carefully for |
|
miscoded malignancies) |
V07.8 |
Other specified prophylactic measure |
V10 |
Personal history of malignancy (screen for subsequent |
|
primaries and/or subsequent treatment) |
V58.0 |
Admission for radiotherapy |
V58.1 |
Admission for chemotherapy |
V66.1 |
Convalescence following radiotherapy |
V66.2 |
Convalescence following chemotherapy |
V67.1 |
Radiation therapy followup |
V67.2 |
Chemotherapy followup |
V71.1 |
Observation for suspected malignant neoplasm |
V76 |
Special screening for malignant neoplasm |
*Carcinoma in situ of the cervix is not reportable; quality control procedures must be in place to make sure if micro-invasion is present, the medical record is not coded to 233.1.
Sources: Jean-Baptiste R, Gebhard IK (eds.). Series IV: Cancer Case Ascertainment. Procedure Guidelines for Cancer Registries. Springfield,
IL: North American Association of Central Cancer Registries, February 2002, p. 48, and Virginia Cancer Registry Quality Assurance Staff, 2006 – 2007.
|